Humana (HUM) EBIAT (2009 - 2026)

Humana has reported EBIAT for 18 years, with the latest figure at $1.2 billion in Q1 2026.

• For the quarter ending Q1 2026, EBIAT fell 4.66% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (down 33.16% YoY), and the FY2025 full-year result was $1.2 billion, changed 0.33% from the prior year.
• EBIAT for Q1 2026 stood at $1.2 billion, up from -$781.0 million in the prior quarter.
• The five-year high for EBIAT was $1.2 billion in Q1 2025, with the low at -$781.0 million in Q4 2025.
• Average EBIAT over 5 years is $523.6 million, with a median of $696.0 million recorded in 2022.
• Year-over-year, EBIAT jumped 114.29% in 2022 and sank 27400.0% in 2023.
• Tracing HUM's EBIAT over 5 years: stood at $2.0 million in 2022, then slumped by 27400.0% to -$546.0 million in 2023, then slipped by 26.37% to -$690.0 million in 2024, then fell by 13.19% to -$781.0 million in 2025, then jumped by 251.86% to $1.2 billion in 2026.
• The last three EBIAT figures came in at $1.2 billion (Q1 2026), -$781.0 million (Q4 2025), and $195.0 million (Q3 2025), per Business Quant data.

Peer Comparison